Emerging Role of Clinical Genetics in CKD

Por Prasad Devarajan, Glenn M. Chertow, Katalin Susztak, Adeera Levin, Rajiv Agarwal, Peter Stenvinkel, Arlene B. Chapman, Bradley A. Warady
Publicado em 2022-04-01

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

Por Ronald D. Perrone, Mohamad-Samer Mouksassi, Klaus Romero, Frank S. Czerwiec, Arlene B. Chapman, Berenice Y. Gitomer, Vicente E. Torres, Dana C. Miskulin, Steve Broadbent, Jean F. Marier
Publicado em 2017-05-01

Pharmacometabolomics reveals racial differences in response to atenolol treatment.

Por William R Wikoff, Reginald F Frye, Hongjie Zhu, Yan Gong, Stephen Boyle, Erik Churchill, Rhonda M Cooper-Dehoff, Amber L Beitelshees, Arlene B Chapman, Oliver Fiehn, Julie A Johnson, Rima Kaddurah-Daouk, Pharmacometabolomics Research Network
Publicado em 2013-01-01

Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort

Por Katelyn A. McKenzie, Mirelle El Ters, Vicente E. Torres, Peter C. Harris, Arlene B. Chapman, Michal Mrug, Frederic F. Rahbari-Oskoui, Kyongtae Ty Bae, Douglas P. Landsittel, William M. Bennett, Alan S. L. Yu, Jonathan D. Mahnken
Publicado em 2018-12-01